ARTICLE | Emerging Company Profile
Commit: Activating the complement pathway to deeply deplete target cells
Launched in May, Danish company’s tech engages C1q to trigger complement-induced killing of cancer or autoimmune cells
October 15, 2024 8:45 PM UTC
Commit is aiming for deep depletion of target cells by activating the most upstream component in the classical complement pathway using bispecific single-domain antibodies. The approach offers a new way to kill autoreactive or cancerous B cells that could compete with CAR T cell and bispecific T cell-engager therapies.
Commit’s technology comes from Denmark’s Aarhus University, considered a center of excellence in complement biology, CEO Krishna Polu told BioCentury. “They’ve been collaborating with pharma and biotech in the complement therapeutics field for a long time.”...